Drug-induced hypersensitivity to artemisinin-based therapies for malaria

Nordmann, Tamara; Borrmann, Steffen; Ramharter, Michael

doi:10.1016/j.pt.2021.08.011

Cited by 7 publications

(6 citation statements)

References 71 publications

(97 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, artemisinin-based dual-or triplecombination therapies are showing satisfactory efficacy. Nonetheless, there is an urgent need for alternative treatments and orally administered drugs with new mechanisms of action to effectively combat the malaria parasite [59,60]. Faced with this need, traditionally used Amazonian plants are important for the discovery of antimalarials against P. falciparum and P. vivax [61].…”

Section: Discussionmentioning

confidence: 99%

Antiplasmodial Activity of Hydroalcoholic Extract from Jucá (Libidibia ferrea) Pods

et al. 2023

View full text Add to dashboard Cite

Malaria is an infectious and parasitic disease caused by protozoa of the genus Plasmodium, which affects millions of people in tropical and subtropical areas. Recently, there have been multiple reports of drug resistance in Plasmodium populations, leading to the search for potential new active compounds against the parasite. Thus, we aimed to evaluate the in vitro antiplasmodial activity and cytotoxicity of the hydroalcoholic extract of Jucá (Libidibia ferrea) in serial concentrations. Jucá was used in the form of a freeze-dried hydroalcoholic extract. For the cytotoxicity assay, the(3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) method with the WI-26VA4 human cell line was used. For the antiplasmodial activity, Plasmodium falciparum synchronized cultures were treated with serial concentrations (0.2 to 50 μg/mL) of the Jucá extract. In terms of the chemical composition of the Jucá extract, gas chromatography coupled to mass spectrometry measurements revealed the main compounds as ellagic acid, valoneic acid dilactone, gallotannin, and gallic acid. The Jucá hydroalcoholic extract did not show cytotoxic activity per MTT, with an IC50 value greater than 100 µg/mL. Regarding the antiplasmodial activity, the Jucá extract presented an IC50 of 11.10 µg/mL with a selective index of nine. Because of its antiplasmodial activity at the tested concentrations and low toxicity, the Jucá extract is presented as a candidate for herbal medicine in the treatment of malaria. To the best of our knowledge, this is the first report of antiplasmodial activity in Jucá.

show abstract

Section: Discussionmentioning

confidence: 99%

Antiplasmodial Activity of Hydroalcoholic Extract from Jucá (Libidibia ferrea) Pods

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Accordingly, the World Health Organization (WHO) recorded up to 216 million cases of malaria and about 445,000 deaths in 2016 only [1]. Development of antimalarial medicine resistance, as well as dramatically diminished sensitivity to artemisinin combination therapy (ACT), is the primary cause of this trend [2][3][4][5][6]. Apart from that, the chemotherapeutic choices for treating and preventing malaria are limited [4].…”

Section: Introductionmentioning

confidence: 99%

“…Development of antimalarial medicine resistance, as well as dramatically diminished sensitivity to artemisinin combination therapy (ACT), is the primary cause of this trend [2][3][4][5][6]. Apart from that, the chemotherapeutic choices for treating and preventing malaria are limited [4]. In light of these circumstances, novel antimalarial drug discovery, particularly medicines associated with multiple mode of action and versatility in terms of efficacy against resistant Plasmodia spp., is critical.…”

Section: Introductionmentioning

confidence: 99%

“…Surprisingly, due to poor physicochemical characteristics and pharmacokinetic profiles, many novel prospective antimalarial medicines are overlooked [7,8]. In accordance with this, novel studies are being performed on the prospect of producing antimalarial salts and co-crystals [4]. The fundamental goal of these investigations is to enhance the physiochemical characteristics of antimalarial medicines without interfering with their bioactivity [9][10][11].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Co-Crystallization of Plant-Derived Antimalarial Drugs: An Alternate Technique for Improved Physicochemical Qualities and Antimalarial Drug Synergy

Makuvara¹

2023

Drug Formulation Design

View full text Add to dashboard Cite

Malaria is a complex disease associated with a variety of epidemiology and clinical symptoms worldwide. Despite the availability of a variety of antimalarial medications, national policies of many countries advocate for a single-medication first-line therapy for the majority of clinical malaria symptoms. However, the studies revealed that using multiple first-line medicines against malaria works more effectively. In this scenario, single-target monotherapy approaches have difficulties since malaria symptoms are seldom caused by single molecular entities. The current work is based on the critical literature review and primary sources as well as secondary databases. The chapter outline is as follows: (1) main antimalarial plant-derived active pharmaceutical ingredients (APD-APIs), (2) limitations of single APD-APIs and shift to multiple first-line therapies in malaria treatment, (3) techniques in the development and properties of APD-APIs co-crystals. The search for novel plant-derived antimalarial medicines and the development of antimalarial co-crystals are essential in the fight against antimalarial drug resistance.

show abstract

“…In the case of malaria, there is a problem of resistance of the parasite to antimalarial drugs [22]. In 1957, the first case of chloroquine-resistant malaria was reported, and then the use of mefloquine and sulfadoxine-pyrimethamine was adopted; however, in the 1980s, resistance against these drugs was also reported [23]. Presently, the most efficacious approach hinges on combination therapy incorporating artemisinin.…”

Section: Introductionmentioning

confidence: 99%

Galectins in Protozoan Parasitic Diseases: Potential Applications in Diagnostics and Therapeutics

Meira,

Silva,

Quadros

et al. 2023

Cells

View full text Add to dashboard Cite

Neglected tropical diseases (NTDs) constitute a group of diseases that generally develop in tropical or subtropical climatic conditions and are related to poverty. Within the spectrum of NTDs, diseases caused by protozoa such as malaria, Chagas disease, and leishmaniasis exhibit elevated mortality rates, thereby constituting a substantial public health concern. Beyond their protozoan etiology, these NTDs share other similarities, such as the challenge of control and the lack of affordable, safe, and effective drugs. In view of the above, the need to explore novel diagnostic predictors and therapeutic targets for the treatment of these parasitic diseases is evident. In this context, galectins are attractive because they are a set of lectins bound to β-galactosides that play key roles in a variety of cellular processes, including host-parasite interaction such as adhesion and entry of parasites into the host cells, and participate in antiparasitic immunity in either a stimulatory or inhibitory manner, especially the galectins-1, -2, -3, and -9. These functions bestow upon galectins significant therapeutic prospects in the context of managing and diagnosing NTDs. Thus, the present review aims to elucidate the potential role of galectins in the diagnosis and treatment of malaria, leishmaniasis, and Chagas disease.

show abstract

Drug-induced hypersensitivity to artemisinin-based therapies for malaria

Cited by 7 publications

References 71 publications

Antiplasmodial Activity of Hydroalcoholic Extract from Jucá (Libidibia ferrea) Pods

Antiplasmodial Activity of Hydroalcoholic Extract from Jucá (Libidibia ferrea) Pods

Co-Crystallization of Plant-Derived Antimalarial Drugs: An Alternate Technique for Improved Physicochemical Qualities and Antimalarial Drug Synergy

Galectins in Protozoan Parasitic Diseases: Potential Applications in Diagnostics and Therapeutics

Contact Info

Product

Resources

About